Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study outlines the temporary or sometimes permanent hair loss caused by cancer treatments, noting it often starts 2-3 weeks after chemotherapy and highlights the need for more research into prevention and treatment strategies for therapy-related alopecia.

This article discusses dermatologic adverse events associated with topoisomerase inhibitors and anthracyclines, such as alopecia and hand-foot syndrome, but reports no new clinical results.

In this study, the safety profile of the prodrug CAP7.1 was found to be similar to other topoisomerase inhibitors, with myelosuppression as the main dose-limiting toxicity.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This review examines the role of topoisomerase-interacting drugs in cancer treatment and emphasizes the importance of understanding their mechanisms for clinical development, but it presents no new results.